1. CSL Shares Suffer Record Plunge as Interim CEO Flags $5B Impairments, Warns Turnaround Timeline Extends
CSL Ltd. shares experienced their sharpest decline on record after the Australian biotechnology giant slashed its full-year profit guidance and disclosed approximately $5 billion in additional impairments, signaling that a business recovery will demand more time than previously anticipated. The announcement came follow...